Literature DB >> 27719626

Metabolic Inhibitors as Antiparasitic Drugs: Pharmacological, Biochemical and Molecular Perspectives.

Suprabhat Mukherjee, Niladri Mukherjee, Prajna Gayen, Priya Roy, Santi P Sinha Babu1.   

Abstract

BACKGROUND: Human diseases caused by the infectious parasites have been one of the major problems throughout the evolutionary journey. Protozoan and metazoan parasitic infections result in a large number of deaths, disabilities and socio-economic loss worldwide to date. Despite the best efforts for developing suitable antiparasitics, these infections take a massive toll on human health. The prevalence of emerging resistance to the existing drugs, lack of efficacy and toxic side effects are as added complications. Being enlisted under 'neglected' category, serious diseases like leishmaniasis, filariasis, trypanosomiasis etc. have failed to draw attention of the governments as well as the pharmaceutical companies. Thus, target specific as well as cost-convenient therapy needs to be employed for the treatment of these diseases and selective targeting of metabolic pathways appears to be the most promising mean.
METHODS: In this context, quality works have been explored for screening either anti-metabolic drugs or selective targets in different groups of parasites. Moreover, complete genome sequencing and metabolomic profiling have provided the initiatives to search for new lethal targets in parasites.
RESULTS: New metabolic targets are being reported from different organelles and other sub-cellular compartments of parasites such as mitochondrion, kinetoplast, apicoplast, glycosome, hydrogenosome, acidocalcisome, plasma membrane, cytoskeleton, etc. Herein, unique findings achieved in identifying new antimetabolic drugs or targets and studying their molecular mode of actions have been reviewed by incorporating existing and upcoming approaches.
CONCLUSION: Considering the alarming scenario of diseases caused by parasites globally, this paper provides a comprehensive review to the scientific community on the development of novel interventions based on metabolic targets to combat the challenges posed by parasites. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Antimetabolic drugs; antiparasitics; cost-convenient therapy; metabolic pathways; metabolic targeting; parasitic diseases

Mesh:

Substances:

Year:  2016        PMID: 27719626     DOI: 10.2174/1389200217666161004143152

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  5 in total

Review 1.  Mining Filarial Genomes for Diagnostic and Therapeutic Targets.

Authors:  Sasisekhar Bennuru; Elise M O'Connell; Papa M Drame; Thomas B Nutman
Journal:  Trends Parasitol       Date:  2017-10-12

2.  Polyphenol enriched ethanolic extract of Cajanus scarabaeoides (L.) Thouars exerts potential antifilarial activity by inducing oxidative stress and programmed cell death.

Authors:  Anindya Sundar Ray; Nikhilesh Joardar; Suprabhat Mukherjee; Chowdhury Habibur Rahaman; Santi P Sinha Babu
Journal:  PLoS One       Date:  2018-12-06       Impact factor: 3.240

3.  Importance of Angomonas deanei KAP4 for kDNA arrangement, cell division and maintenance of the host-bacterium relationship.

Authors:  Camila Silva Gonçalves; Carolina Moura Costa Catta-Preta; Bruno Repolês; Jeremy C Mottram; Wanderley De Souza; Carlos Renato Machado; Maria Cristina M Motta
Journal:  Sci Rep       Date:  2021-04-28       Impact factor: 4.379

4.  m1A methylation modification patterns and metabolic characteristics in hepatocellular carcinoma.

Authors:  Chengcheng Tong; Wei Wang; Chiyi He
Journal:  BMC Gastroenterol       Date:  2022-03-03       Impact factor: 3.067

5.  Quinolone-fused cyclic sulfonamide as a novel benign antifilarial agent.

Authors:  Suprabhat Mukherjee; Nikhilesh Joardar; Shovan Mondal; Andrea Schiefer; Achim Hoerauf; Kenneth Pfarr; Santi P Sinha Babu
Journal:  Sci Rep       Date:  2018-08-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.